Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

by Prabhu, Jyothi S. , Carbone, Daniela , Nair, Madhumathy G. , Eng, Huiyan , Yap, Kenneth C. H. , Teh, Daniel B. L. , Diana, Patrizia , Davids, Matthew S. , Fruman, David A. , Jones, Robert H. , Jacot, William , Pecoraro, Camilla , Glaviano, Antonino , Javidi-Sharifi, Nathalie R. , Baird, Richard D. , Stebbing, Justin , Brown, Jennifer R. , Kumar, Alan P. , Kulke, Matthew H. , Lin, Kevin H. , Sethi, Gautam , Makvandi, Pooyan , Cavalieri, Vincenzo , Lam, Hiu Y. , Toska, Eneda , Foo, Aaron S. C. , Geoerger, Birgit

in 1-Phosphatidylinositol 3-kinase / AKT inhibitors / AKT protein / Allosteric mTOR inhibitors / Antineoplastic drugs / Biochemistry, Molecular Biology / Biomedical and Life Sciences / Biomedicine / Bone cancer / Brain cancer / Breast cancer / Cancer / Cancer Research / Care and treatment / Cell cycle / Cell growth / Cell survival / Cellular signal transduction / Cervical cancer / Clinical trials / Development and progression / Disease resistance / Dual PI3K/mTOR inhibitors / Estrogens / Gallbladder cancer / Gastric cancer / Genomics / Growth factors / Health aspects / Humans / Hyperactivity / Immunotherapy / Isoform-specific PI3K inhibitors / Kidney cancer / Kinases / Leukemia / Life Sciences / Lung cancer / Medical prognosis / Melanoma / Metastasis / Mutation / Neoplasms / Neoplasms - drug therapy / Neoplasms - genetics / Oncology / Ovarian cancer / Pan PI3K inhibitors / Pharmaceutical sciences / Pharmacology / Phosphatidylinositol 3-Kinases / PI3K/AKT/mTORC pathway / Prostate cancer / Proto-Oncogene Proteins c-akt / PTEN protein / Review / Sarcoma / Signal Transduction / Thyroid cancer / TOR protein / TOR Serine-Threonine Kinases / Transcription factors / Treatment resistance / Tumors

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

2023

Confirm

Do you wish to request the book?

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

Prabhu, Jyothi S.,

Carbone, Daniela,

Nair, Madhumathy G.,

Eng, Huiyan,

Yap, Kenneth C. H.,

Teh, Daniel B. L.,

Diana, Patrizia,

Davids, Matthew S.,

Fruman, David A.,

Jones, Robert H.,

Jacot, William,

Pecoraro, Camilla,

Glaviano, Antonino,

Javidi-Sharifi, Nathalie R.,

Baird, Richard D.,

Stebbing, Justin,

Brown, Jennifer R.,

Kumar, Alan P.,

Kulke, Matthew H.,

Lin, Kevin H.,

Sethi, Gautam,

Makvandi, Pooyan,

Cavalieri, Vincenzo,

Lam, Hiu Y.,

Toska, Eneda,

Foo, Aaron S. C.,

Geoerger, Birgit

2023

Overview

The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer development. The PAM axis is the most frequently activated signaling pathway in human cancer and is often implicated in resistance to anticancer therapies. Dysfunction of components of this pathway such as hyperactivity of PI3K, loss of function of PTEN, and gain-of-function of AKT, are notorious drivers of treatment resistance and disease progression in cancer. In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR inhibitors as monotherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy for overcoming treatment resistance. Finally, the major mechanisms of resistance to PAM signaling targeted therapies, including PAM signaling in immunology and immunotherapies are also discussed.

Share this book

Add to My Shelf

Publisher

BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC

Subject

1-Phosphatidylinositol 3-kinase

/ AKT inhibitors

/ AKT protein

/ Allosteric mTOR inhibitors

/ Antineoplastic drugs

/ Biochemistry, Molecular Biology

/ Biomedical and Life Sciences